KR100874052B1 - 젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도 - Google Patents

젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도 Download PDF

Info

Publication number
KR100874052B1
KR100874052B1 KR1020077013628A KR20077013628A KR100874052B1 KR 100874052 B1 KR100874052 B1 KR 100874052B1 KR 1020077013628 A KR1020077013628 A KR 1020077013628A KR 20077013628 A KR20077013628 A KR 20077013628A KR 100874052 B1 KR100874052 B1 KR 100874052B1
Authority
KR
South Korea
Prior art keywords
gemcitabine
compound
formula
cancer
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077013628A
Other languages
English (en)
Korean (ko)
Other versions
KR20070086308A (ko
Inventor
다비드 마이클 벤더
다비드 마이클 레믹
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20070086308A publication Critical patent/KR20070086308A/ko
Application granted granted Critical
Publication of KR100874052B1 publication Critical patent/KR100874052B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
KR1020077013628A 2004-12-17 2005-11-30 젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도 Expired - Fee Related KR100874052B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63742204P 2004-12-17 2004-12-17
US60/637,422 2004-12-17

Publications (2)

Publication Number Publication Date
KR20070086308A KR20070086308A (ko) 2007-08-27
KR100874052B1 true KR100874052B1 (ko) 2008-12-12

Family

ID=36168678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013628A Expired - Fee Related KR100874052B1 (ko) 2004-12-17 2005-11-30 젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도

Country Status (31)

Country Link
US (1) US7691827B2 (enExample)
EP (1) EP1831237B1 (enExample)
JP (1) JP5022911B2 (enExample)
KR (1) KR100874052B1 (enExample)
CN (1) CN101080417B (enExample)
AR (1) AR055009A1 (enExample)
AT (1) ATE405573T1 (enExample)
AU (1) AU2005316922B2 (enExample)
BR (1) BRPI0519117A2 (enExample)
CA (1) CA2589850C (enExample)
CY (1) CY1108447T1 (enExample)
DE (1) DE602005009255D1 (enExample)
DK (1) DK1831237T3 (enExample)
EA (1) EA011868B1 (enExample)
ES (1) ES2310860T3 (enExample)
HR (1) HRP20080529T3 (enExample)
IL (1) IL183666A (enExample)
MA (1) MA29154B1 (enExample)
MX (1) MX2007007228A (enExample)
MY (1) MY143677A (enExample)
NO (1) NO20073368L (enExample)
NZ (1) NZ554732A (enExample)
PE (1) PE20060771A1 (enExample)
PL (1) PL1831237T3 (enExample)
PT (1) PT1831237E (enExample)
RS (1) RS50629B (enExample)
SI (1) SI1831237T1 (enExample)
TW (1) TWI326687B (enExample)
UA (1) UA86119C2 (enExample)
WO (1) WO2006065525A1 (enExample)
ZA (1) ZA200705019B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652633C (en) * 2006-06-21 2014-03-25 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101525361B (zh) * 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
CA2890359A1 (en) 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
KR20150082606A (ko) 2012-11-13 2015-07-15 보옌 테라퓨틱스, 인크. 겜시타빈 전구약물 및 그의 용도
US10059733B2 (en) 2014-03-03 2018-08-28 Nucorion Pharmaceuticals, Inc. Gemcitabine analogs
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN113166189A (zh) * 2018-04-26 2021-07-23 纳米医学控股有限公司 吉西他滨两亲性前体药物
CN108864250A (zh) * 2018-05-29 2018-11-23 北京大学 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用
KR20210057025A (ko) * 2018-08-03 2021-05-20 셀릭스 바이오 프라이빗 리미티드 암의 치료를 위한 조성물 및 방법
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
PL442924A1 (pl) * 2022-11-23 2024-05-27 Politechnika Śląska Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032762A1 (en) * 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
RU2131880C1 (ru) * 1992-06-22 1999-06-20 Эли Лилли Энд Компани Способ получения обогащенных бета-аномером нуклеозидов
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032762A1 (en) * 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
ES2310860T3 (es) 2009-01-16
HK1109903A1 (en) 2008-06-27
HRP20080529T3 (en) 2008-12-31
UA86119C2 (ru) 2009-03-25
DK1831237T3 (da) 2008-10-27
ZA200705019B (en) 2008-10-29
ATE405573T1 (de) 2008-09-15
IL183666A0 (en) 2007-09-20
CY1108447T1 (el) 2014-04-09
NZ554732A (en) 2010-09-30
PT1831237E (pt) 2008-09-22
CA2589850A1 (en) 2006-06-22
TW200634023A (en) 2006-10-01
DE602005009255D1 (de) 2008-10-02
TWI326687B (en) 2010-07-01
EA200701300A1 (ru) 2007-10-26
BRPI0519117A2 (pt) 2008-12-23
EA011868B1 (ru) 2009-06-30
PE20060771A1 (es) 2006-09-23
CN101080417A (zh) 2007-11-28
RS50629B (sr) 2010-06-30
KR20070086308A (ko) 2007-08-27
EP1831237A1 (en) 2007-09-12
MY143677A (en) 2011-06-30
CN101080417B (zh) 2011-01-19
AU2005316922B2 (en) 2011-08-25
MA29154B1 (fr) 2008-01-02
US20090156547A1 (en) 2009-06-18
IL183666A (en) 2011-09-27
EP1831237B1 (en) 2008-08-20
JP5022911B2 (ja) 2012-09-12
JP2008524218A (ja) 2008-07-10
WO2006065525A1 (en) 2006-06-22
CA2589850C (en) 2012-05-01
AR055009A1 (es) 2007-08-01
MX2007007228A (es) 2007-08-14
SI1831237T1 (sl) 2009-02-28
PL1831237T3 (pl) 2009-01-30
NO20073368L (no) 2007-07-16
AU2005316922A1 (en) 2006-06-22
US7691827B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
KR100874052B1 (ko) 젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도
AU610344B2 (en) 2'-deoxy-5-fluorouridine derivatives
US8114854B2 (en) Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
WO2008132541A2 (en) Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents
CN101402667B (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
CA2707593A1 (en) Clofarabine phospholipid derivatives
HK1109903B (en) Amide prodrug of gemcitabine, compositions and use thereof
EP3470403B1 (en) Taxoid compound and preparation method and use thereof
HK1116197A (en) Amide prodrug of gemcitabine, compositions and use thereof
BRPI0713615A2 (pt) Formas cristalinas de pró-fármacos de amida de gemcitabina, composições de uso das mesmas
WO2011070152A2 (fr) Nouveaux composés antiviraux, analogues de la 3-deazauridine aryles en position c3

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20141128

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151209

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151209